Browsing by Subject "Down syndrome"
Now showing items 1-7 of 7
-
Conference Object
Artificial neural networks for non-invasive chromosomal abnormality screening of fetuses
(2010)A large number of different neural network structures have been constructed, trained and tested to a large data base of pregnant women characteristics, aiming at generating a classifier-predictor for the presence of ...
-
Article
Cancer and pregnancy: What should we know about the management with systemic treatment of pregnant women with cancer?
(2011)The incidence of cancer during pregnancy is a rare phenomenon and is estimated to occur in 1:1000 pregnancies. This co-existence is likely to rise since the delay of childbearing to the later reproductive age is nowadays ...
-
Article
-
Conference Object
First trimester diagnosis of trisomy-21 using artificial neural networks
(2010)Langdon Down in 1866 reported on a syndrome in which individuals have skin appearing to be too large for the body, a nose small and a flat face. This is a chromosomal disorder caused by the presence of all or part of an ...
-
Article
A new non-invasive prenatal diagnosis of Down syndrome through epigenetic markers and real-time qPCR
(2012)Introduction: Non-invasive prenatal diagnosis (NIPD) of Down syndrome is rapidly evolving. Currently, two applications for NIPD of Down syndrome have been developed with potential and have displayed positive results
-
Article
Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors
(2010)The association of cancer and pregnancy is increasingly encountered nowadays in clinical practice. Due to the relative rarity of the situation, it lacks a systematized approach. Different systemic therapies are used in ...
-
Article
Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors
(2010)Managing pregnant patients with hematological tumors pose even more conflicts compared to solid tumors. Unlike the majority of solid tumors, hematological malignancies are potentially curable; hence it is important to ...